VDAC2 and Parkinson disease: Based on this study, we believe that the physiological function impairment of APP and SNCA is the early core pathology to induce mitochondrial dysfunction at the early stage of AD and PD, while the IP3R1-Grp75-VDAC2 axis might be the common drug target of these two diseases.